Allos Therapeutics (ALTH) Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that the Company has received notification from the U.S. Food and Drug Administration's (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
